RSS-Feed abonnieren
DOI: 10.1160/TH04-10-0657
Medical conditions increasing the risk of chronic thromboembolic pulmonary hypertension
Grant support: This research was supported by the Austrian fellowship grant FWF P13834-MED (to IML), the österreichischer Selbsthilfeverein Lungenhochdruck and the Ludwig Boltzmann Institutes for Cardiovascular Research and Thrombosis Research.Publikationsverlauf
Received
10. Oktober 2004
Accepted after revision
28. Februar 2004
Publikationsdatum:
14. Dezember 2017 (online)
Summary
Chronic thromboembolic pulmonary hypertension (CTEPH) is characterized by organized thromboemboli that obstruct the pulmonary vascular bed. Although CTEPH is a serious complication of acute symptomatic pulmonary embolism in 4% of cases, signs, symptoms and classical risk factors for venous thromboembolism are lacking. The aim of the present study was to identify medical conditions conferring an increased risk of CTEPH. We performed a case-control-study comparing 109 consecutive CTEPH patients to 187 patients with acute pulmonary embolism that was confirmed by a high probability lung scan. Splenectomy (odds ratio=13, 95% CI 2.7–127), ventriculoatrial (VA-) shunt for the treatment of hydrocephalus (odds ratio=13, 95% CI 2.5–129) and chronic inflammatory disorders, such as osteomyelitis and inflammatory bowel disease (IBD, odds ratio=67, 95% CI 7.9–8832) were associated with an increased risk of CTEPH.
-
References
- 1 Pengo V, Lensing AW, Prins MH. et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 2004; 350: 2257-64.
- 2 Ribeiro A, Lindmarker P, Johnsson H. et al. Pulmonary embolism: one-year follow-up with echocardiography doppler and five-year survival analysis. Circulation 1999; 99: 1325-30.
- 3 Lang IM. Chronic thromboembolic pulmonary hypertension-- not so rare after all. N Engl J Med 2004; 350: 2236-8.
- 4 Wolf M, Boyer-Neumann C, Parent F. et al. Thrombotic risk factors in pulmonary hypertension. Eur Respir J 2000; 15: 395-9.
- 5 Fedullo PF, Auger WR, Kerr KM. et al. Chronic thromboembolic pulmonary hypertension. N Engl J Med 2001; 345: 1465-72.
- 6 Bonderman D, Turecek PL, Jakowitsch J. et al. High prevalence of elevated clotting factor VIII in chronic thromboembolic pulmonary hypertension. Thromb Haemost 2003; 90: 372-6.
- 7 Cappellini MD, Robbiolo L, Bottasso BM. et al. Venous thromboembolism and hypercoagulability in splenectomized patients with thalassaemia intermedia. Br J Haematol 2000; 111: 467-73.
- 8 Stewart GW, Amess JA, Eber SW. et al. Thromboembolic disease after splenectomy for hereditary stomatocytosis. Br J Haematol 1996; 93: 303-10.
- 9 Chou R, DeLoughery TG. Recurrent thromboembolic disease following splenectomy for pyruvate kinase deficiency. Am J Hematol 2001; 67: 197-9.
- 10 Favara BE, Paul RN. Thromboembolism and cor pulmonale complicating ventriculovenous shunt. JAMA 1967; 199: 668-71.
- 11 Unnithan RR, Bahuleyan CG, Sambasivan M. et al. Ventriculo-atrial shunt producing pulmonary hypertension. J Assoc Physicians India 1984; 32: 1000-1.
- 12 Trowitzsch E, Ostrejz M, Evers D. et al. Echocardiographic proof of pulmonary hypertension with irreversible increased resistance in the pulmonary circulation as a complication after placement of a ventriculo- atrial shunt for internal hydrocephalus. Eur J Pediatr Surg 1992; 2: 361-4.
- 13 Haasnoot K, van Vught AJ. Pulmonary hypertension complicating a ventriculo-atrial shunt. Eur J Pediatr 1992; 151: 748-50.
- 14 Drucker MH, Vanek VW, Franco AA. et al. Thromboembolic complications of ventriculoatrial shunts. Surg Neurol 1984; 22: 444-8.
- 15 Pascual JM, Prakash UB. Development of pulmonary hypertension after placement of a ventriculoatrial shunt. Mayo Clin Proc 1993; 68: 1177-82.
- 16 Rao PS, Molthan ME, Lipow HW. Cor pulmonale as a complication of ventriculoatrial shunts. Case report. J Neurosurg 1970; 33: 221-5.
- 17 Ralston DR, St John RC. Progressive shortness of breath in a 50-year-old man with ulcerative colitis. Chest 1996; 110: 1608-10.
- 18 Schlesselmann JJ. Case control studies: design, conduct, analysis. In: Press OU, ed; New York, Oxford: 1982
- 19 Jamieson SW. Pulmonary thromboendarterectomy [editorial]. Heart 1998; 79: 118-20.
- 20 Thistlethwaite PA, Mo M, Madani MM. et al. Operative classification of thromboembolic disease determines outcome after pulmonary endarterectomy. J Thorac Cardiovasc Surg 2002; 124: 1203-11.
- 21 Seligsohn U, Lubetsky A. Genetic susceptibility to venous thrombosis. N Engl J Med 2001; 344: 1222-31.
- 22 Value of the ventilation/perfusion scan in acute pulmonary embolism Results of the prospective investigation of pulmonary embolism diagnosis (PIOPED). The PIOPED Investigators. JAMA 1990; 263: 2753-9.
- 23 Lennard-Jones J, Shivananda S. Clinical uniformity of inflammatory bowel disease at presentation and during the first year of disease in the north and south of Europe. Eur J Gastroenterol Hepatol 1997; 9: 353-9.
- 24 Freeman HJ. Osteomyelitis and osteonecrosis in inflammatory bowel disease. Can J Gastroenterol 1997; 11: 601-6.
- 25 Heinze G, Schemper M. A solution to the problem of separation in logistic regression. Stat Med 2002; 21: 2409-19.
- 26 Heinze G, Ploner M. Fixing the nonconvergence bug in logistic regression with SPLUS and SAS. Comput Methods Programs Biomed 2003; 71: 181-7.
- 27 Miyamoto S, Nagaya N, Satoh T. et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 2000; 161: 487-92.
- 28 Hoeper MM, Niedermeyer J, Hoffmeyer F. et al. Pulmonary hypertension after splenectomy?. Ann Intern Med 1999; 130: 506-9.
- 29 Moser KM, Auger WR, Fedullo PF. Chronic majorvessel thromboembolic pulmonary hypertension. Circulation 1990; 81: 1735-43.
- 30 Schoenbaum SC, Gardner P, Shillito J. Infections of cerebrospinal fluid shunts: epidemiology, clinical manifestations, and therapy. J Infect Dis 1975; 131: 543-52.
- 31 Ejstrud P, Kristensen B, Hansen JB. et al. Risk and patterns of bacteraemia after splenectomy: a population- based study. Scand J Infect Dis 2000; 32: 521-5.
- 32 Olman MA, Marsh JJ, Lang IM. et al. Endogenous fibrinolytic system in chronic large-vessel thromboembolic pulmonary hypertension. Circulation 1992; 86: 1241-8.
- 33 Lang IM, Marsh JJ, Olman MA. et al. Parallel analysis of tissue-type plasminogen activator and type 1 plasminogen activator inhibitor in plasma and endothelial cells derived from patients with chronic pulmonary thromboemboli. Circulation 1994; 90: 706-12.
- 34 Lang IM, Marsh JJ, Olman MA. et al. Expression of type 1 plasminogen activator inhibitor in chronic pulmonary thromboemboli. Circulation 1994; 89: 2715-21.
- 35 Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327: 76-81.
- 36 Abenhaim L, Moride Y, Brenot F. et al. Appetitesuppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med 1996; 335: 609-16.
- 37 Humbert M, Nunes H, Sitbon O. et al. Risk factors for pulmonary arterial hypertension. Clin Chest Med 2001; 22: 459-75.
- 38 McGoon MD. Task force on diagnosis and assessment, Third World Symposium on Pulmonary Arterial Hypertension, Venice. 2003
- 39 McGoon M, Gutterman D, Steen V. et al. Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004; 126 (Suppl.) 14S-34S.